115 related articles for article (PubMed ID: 15940861)
1. Evidence in Vioxx suits shows intervention by Merck officials.
Berenson A
N Y Times Web; 2005 Apr; ():A1, A32. PubMed ID: 15940861
[No Abstract] [Full Text] [Related]
2. Manipulating a journal article.
N Y Times Web; 2005 Dec; ():WK11. PubMed ID: 16453395
[No Abstract] [Full Text] [Related]
3. Medical journal criticizes Merck over Vioxx data.
Berenson A
N Y Times Web; 2005 Dec; ():A1, C13. PubMed ID: 16456990
[No Abstract] [Full Text] [Related]
4. NEJM editor gives pretrial evidence in Vioxx case.
Tanne JH
BMJ; 2006 Feb; 332(7536):255. PubMed ID: 16455704
[No Abstract] [Full Text] [Related]
5. Merck VIOXX "warning" is questioned.
Allen TS; Henderson JH
Tex Med; 2005 May; 101(5):5-6. PubMed ID: 15948521
[No Abstract] [Full Text] [Related]
6. Despite warnings, drug giant took long path to Vioxx recall.
Berenson A; Harris G; Meier B; Pollack A
N Y Times Web; 2004 Nov; ():A1, A32. PubMed ID: 15599982
[No Abstract] [Full Text] [Related]
7. Needed: closer scrutiny of clinical trials.
Gulhati CM
Indian J Med Ethics; 2004; 1(1):4-5. PubMed ID: 16370061
[No Abstract] [Full Text] [Related]
8. Vioxx doctors wooed by Merck are now its foes.
Tesoriero HW
Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
[No Abstract] [Full Text] [Related]
9. Despite vow, drug makers still withhold data.
Berenson A
N Y Times Web; 2005 May; ():A1, C3. PubMed ID: 15952254
[No Abstract] [Full Text] [Related]
10. British rethinking test rules after drug trial nearly kills 6.
Rosenthal E
N Y Times Web; 2006 Apr; ():A1, A6. PubMed ID: 16642579
[No Abstract] [Full Text] [Related]
11. For the uninsured, drug trials are health care.
Kolata G; Eichenwald K
N Y Times Web; 1999 Jun; ():A1, C12. PubMed ID: 11647664
[No Abstract] [Full Text] [Related]
12. How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as "punching bag".
Armstrong D
Wall St J (East Ed); 2006 May; ():A1, A10. PubMed ID: 16848016
[No Abstract] [Full Text] [Related]
13. The lessons of Vioxx--drug safety and sales.
Waxman HA
N Engl J Med; 2005 Jun; 352(25):2576-8. PubMed ID: 15972862
[No Abstract] [Full Text] [Related]
14. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors.
Couzin J
Science; 2004 Oct; 306(5695):384-5. PubMed ID: 15486258
[No Abstract] [Full Text] [Related]
15. Failing the public health--rofecoxib, Merck, and the FDA.
Topol EJ
N Engl J Med; 2004 Oct; 351(17):1707-9. PubMed ID: 15470193
[No Abstract] [Full Text] [Related]
16. Rofecoxib (Vioxx) voluntarily withdrawn from market.
Sibbald B
CMAJ; 2004 Oct; 171(9):1027-8. PubMed ID: 15505253
[No Abstract] [Full Text] [Related]
17. Patients in test won't get drug, Amgen decides.
Pollack A
N Y Times Web; 2005 Feb; ():C1, C2. PubMed ID: 15742509
[No Abstract] [Full Text] [Related]
18. Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.
Epstein RA
Yale J Health Policy Law Ethics; 2005; 5(2):741-70. PubMed ID: 16052898
[No Abstract] [Full Text] [Related]
19. Quebec allows Vioxx class-action suit.
Sibbald B
CMAJ; 2007 Jan; 176(1):20. PubMed ID: 17200378
[No Abstract] [Full Text] [Related]
20. The vexations of Vioxx.
Sibbald B
CMAJ; 2006 Feb; 174(4):444-5. PubMed ID: 16477046
[No Abstract] [Full Text] [Related]
[Next] [New Search]
